Programs identify therapies and integrate molecular techniques in clinical trials for solid tumors, especially prostate cancer, and hematological cancers. Strict links to IOSI, SAKK or IELSG cooperative groups. IOR also owns the patent of novel anticancer molecules.

Location
Canton
Facts & figures
  • Type of organization
    Foundation
  • Year of foundation
    2003
  • Number of employees in Switzerland
    50-149
Key business

You may also be interested in